Weder Jürgen K P, Hinkers Sabine C
Institut für Lebensmittelchemie, Technische Universität München, Lichtenbergstrasse 4, 85748 Garching, Germany.
J Agric Food Chem. 2004 Jun 30;52(13):4219-26. doi: 10.1021/jf030768d.
The complete primary structure of the lentil (Lens culinaris) trypsin-chymotrypsin inhibitor LCI-1.7 was determined by conventional methods in order to find relationships between partial sequences and the difference in action against human and bovine chymotrypsin. As other Bowman-Birk type inhibitors, LCI-1.7 contained 68 amino acid residues, seven disulfide bridges, and two reactive sites, Arg16-Ser17 for trypsin and Tyr42-Ser43 for chymotrypsin. Evaluation of sequence homologies showed that it belonged to the group III Bowman-Birk inhibitors. The atypical additional binding site of LCI-1.7 for human chymotrypsin was discussed and compared with such binding sites of two other Bowman-Birk inhibitors, the Bowman-Birk soybean proteinase inhibitor BBI, and the lima bean proteinase inhibitor LBI I, for human and bovine trypsin and chymotrypsin. A concept to reduce the action of these inhibitors against human enzymes by genetic engineering was proposed.
为了找出部分序列与扁豆胰蛋白酶 - 糜蛋白酶抑制剂LCI - 1.7对人源和牛源糜蛋白酶作用差异之间的关系,采用常规方法测定了扁豆(Lens culinaris)胰蛋白酶 - 糜蛋白酶抑制剂LCI - 1.7的完整一级结构。与其他鲍曼 - 伯克型抑制剂一样,LCI - 1.7含有68个氨基酸残基及7个二硫键,有两个活性位点,分别为针对胰蛋白酶的Arg16 - Ser17和针对糜蛋白酶的Tyr42 - Ser43。序列同源性评估表明它属于III组鲍曼 - 伯克抑制剂。文中讨论了LCI - 1.7对人源糜蛋白酶的非典型额外结合位点,并将其与另外两种鲍曼 - 伯克抑制剂,即鲍曼 - 伯克大豆蛋白酶抑制剂BBI和利马豆蛋白酶抑制剂LBI I针对人源和牛源胰蛋白酶及糜蛋白酶的此类结合位点进行了比较。还提出了通过基因工程降低这些抑制剂对人源酶作用的构想。